Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 14, 2018. The report details a strategic regulatory milestone for ViiV Healthcare, a global specialist HIV company majority-owned by GSK. The filing announces the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a new single-tablet, two-drug regimen combining dolutegravir and lamivudine for the treatment of HIV-1 infection.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes and Operational Updates
- Regulatory Submission: ViiV Healthcare submitted an MAA to the EMA for a dolutegravir/lamivudine single-tablet regimen.
- Clinical Basis: The submission relies on the GEMINI 1 and 2 studies, which included over 1,400 HIV-1 infected adults with baseline viral loads up to 500,000 c/mL.
- Therapeutic Shift: The proposed regimen aims to replace traditional three-drug regimens with a two-drug option, reducing the medication burden for patients.
- Future Filings: A New Drug Application (NDA) to the US FDA is planned for October 2018, utilizing a priority review voucher. Other global submissions are anticipated in the coming months.
Outlook, Risks, and Management Commentary
Management, including ViiV Healthcare CEO Deborah Waterhouse and Chief Scientific Officer John C Pottage, Jr., emphasized a commitment to reducing the number of medicines patients must take for life-long treatment. They view this submission as a step toward a "new era" in HIV treatment for newly diagnosed patients.
Risks and Contingencies:
- Regulatory Approval: The filing is contingent upon approval by the EMA and other global regulators.
- Safety Warnings: The filing includes detailed safety information for dolutegravir (Tivicay) and lamivudine (Epivir), including risks of hypersensitivity, hepatotoxicity, embryo-fetal toxicity (neural tube defects), and immune reconstitution syndrome.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks outlined in their 2017 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the status of the EMA review process for the dolutegravir/lamivudine MAA.
- Confirm the timeline and outcome of the planned October 2018 FDA NDA submission.
- Review the full prescribing information for Tivicay and Epivir to understand specific contraindications and safety monitoring requirements.
- Monitor for any updates on the GEMINI 1 and 2 study results beyond the initial presentation at the 2018 International AIDS Society meeting.